FATEMEH MONTAZER, REZA ALIZADEH-NAVAEI
Turkish Journal of Oncology - 2019;34(4):243-247
OBJECTIVE Glucose transporter 1(GLUT1), as a member of the glucose transport facilitator family, has a role in some cancers. The present study aimed to investigate the expression level of GLUT1 in papillary thyroid cancer. METHODS This cross-sectional study was conducted in 2016 on tissue samples of patients, aged 18-60 years old, recently diagnosed with papillary thyroid cancer based on the WHO criteria. Anti-GLUT1 rat monoclonal antibody and LSAB Kit were used for immunohistochemistry. The intensity of marker expression was classified into three levels as follows: low, moderate and high. Other microscopic parameters, such as capsule invasion and tumor type, were also studied. RESULTS The present study was conducted in 67 patients (mean age: 37.2±10.3 years old), including 37 (55.2%) female patients. GLUT1 was expressed in all participants with papillary thyroid cancer, and high levels were observed in 64.2% of the patients. The elevated expression level was more frequent in men (p=0.04); however, no significant relationship was found between the expression level of GLUT1 and the pattern, capsule invasion, and lymph node metastases (p>0.05). We observed no significant relationship between mean age and mean tumor size of patients with different expression levels of GLUT1. CONCLUSION GLUT1 was expressed at high levels in many patients with papillary thyroid cancer. However, there was no significant relationship between the expression of marker and tumor properties.
